BioCryst Pharmaceuticals (NASDAQ:BCRX) stands at a pivotal moment as it transitions from a development-stage biotech to a profitable commercial enterprise. With a market cap of $2.29 billion, the stock has analyst attention, with consensus targets suggesting roughly 27% upside potential.
Its lead product Orladeyo, an oral therapy for hereditary angioedema (HAE), is gaining momentum. Recent regulatory wins and financial guidance show the company is executing its plan.
In December 2025, the FDA approved Orladeyo for children aged 2-11 with HAE. This expands the addressable market and could add approximately $100 million in revenue.
BioCryst reported preliminary Q4 2025 Orladeyo sales of about $151 million, meeting expectations. Full-year 2025 revenue is projected at $590-$600 million.
For 2026, Orladeyo sales guidance is $625-$645 million, representing about 13% year-over-year growth at the midpoint.
The company ended 2025 with $388 million in cash. Management expects non-GAAP profitability in 2026. Analysts predict profitability this year.
Beyond Orladeyo, BioCryst is advancing BCX17725, a KLK5 inhibitor for Netherton syndrome. First patient data is expected by end of 2026, a key catalyst.
BioCryst targets combined revenue of $1.8 billion or more by 2033, driven by US patient growth, price increases, international expansion, and pipeline assets.
